Earnings & Reporting

The coffee giant posts impressive 2025 results amid high inflation, paving the way for its blockbuster acquisition by Keurig Dr Pepper. What's next?

With key conferences ahead, Supernus Pharmaceuticals must prove its strategy can deliver growth in the competitive central nervous system drug landscape.

The department store chain reported strong earnings that surpassed analyst estimates, but declining sales and margin pressure reveal a complex path forward.

Fresh off its first profitable year and with a new CEO, Remitly launches a major investor tour to detail its ambitious diversification strategy.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.

The French banking giant finalizes a major capital reduction and progresses on a new buyback, signaling strong confidence and rewarding investors.

GameChange Energy acquires Terrasmart's eBOS unit, expanding its module-to-grid offerings and boosting U.S. solar manufacturing in a major industry shift.

Bitcoin miner Abits Group raises needed cash in a dilutive offering, sending its stock plunging and shining a spotlight on its controversial dealmaker.

With strong growth in key sectors but weakness in others, Plexus management faces a pivotal moment at the upcoming Raymond James investor conference.

Renoworks strengthens its board with a tech investment expert, signaling a strategic push to scale its AI platform and capitalize on the digital home market.

Mawer Investment Management names industry veteran Eric Wetlaufer as interim CEO, ensuring leadership continuity as Bruce Geddes takes a personal leave.

Amid financial headwinds, CISO Global appoints a new EVP to accelerate AI innovation, enhance operational efficiency, and gain a competitive edge.

As cardiovascular disease affects nearly half of US adults, experts are urging a shift to existing, life-saving therapies that are widely ignored.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

With revenue growth tied to shrinking margins, illumin's upcoming 2025 earnings report is a critical test of its strategy in a shifting ad tech world.

The pizza giant posts robust sales and expands market share, crediting its 'Hungry for MORE' strategy and rewarding investors with a major dividend boost.

New research reveals two-thirds of Australians are just scraping by, forcing a hard look at budgets, aspirations, and the tools needed to survive.

With its stock under pressure despite strong results, Box will use a key conference to prove its AI-powered content platform is the future of enterprise work.

As PBF Energy prepares for key investor conferences, all eyes are on its strategy for balancing traditional refining with its major renewable fuels venture.